Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Synthesis and Applications in Catalysis or as Anticancer and Antimicrobial...
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Synthesis and Applications in Catalysis or as Anticancer and Antimicrobial Agents of Unique Organometallic Compounds

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Organometallic Chemistry".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 3549

Special Issue Editors

Dr. Giulio Bresciani

E-Mail Website
Guest Editor
Department of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, I-56124 Pisa, Italy
Interests: coordination compounds; organometallic synthesis; catalysis; CO2 activation; bioinorganic; metals in medicine
Prof. Dr. Guido Pampaloni

E-Mail Website
Guest Editor
Department of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, I-56124 Pisa, Italy
Interests: organometallics; metal halides; inorganic chemistry; activation of small molecules

Special Issue Information

Dear Colleagues,

For several years, organometallic complexes have occupied a prominent position in modern chemistry and their properties (catalytic, reactive and biological) are widely studied for their possible uses, both in basic chemistry and in industrial processes. To showcase the latest developments in this area, this Special Issue on the “Synthesis and Applications in Catalysis or as Anticancer and Antimicrobial Agents of Unique Organometallic Compounds” invites original articles, review papers and perspective comments concerning the synthesis, characterization and application (catalytic and/or biomedical) of new organometallic compounds.

The goal of this Special Issue is to collect manuscripts that focus on the synthesis and characterization of such compounds and provide other authors with guidelines to the development and design of new organometallic compounds for catalytic or biological uses.

Dr. Giulio Bresciani
Prof. Dr. Guido Pampaloni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • organometallic synthesis
  • inorganic chemistry
  • homogeneous catalysis
  • heterogeneous catalysis
  • bioinorganic
  • metals in medicine
  • anticancer metal drugs

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2776 KiB  
Article
Synthesis and Antiproliferative Insights of Lipophilic Ru(II)-Hydroxy Stearic Acid Hybrid Species
by Giacomo Drius, Silvia Bordoni, Carla Boga, Magda Monari, Jessica Fiori, Erika Esposito, Chiara Zalambani, Luca Pincigher, Giovanna Farruggia, Natalia Calonghi and Gabriele Micheletti
Molecules 2023, 28(10), 4051; https://doi.org/10.3390/molecules28104051 - 12 May 2023
Viewed by 1442
Abstract
Metallodrugs represent a combination of multifunctionalities that are present concomitantly and can act differently on diverse biotargets. Their efficacy is often related to the lipophilic features exhibited both by long carbo-chains and the phosphine ligands. Three Ru(II) complexes containing hydroxy stearic acids (HSAs) [...] Read more.
Metallodrugs represent a combination of multifunctionalities that are present concomitantly and can act differently on diverse biotargets. Their efficacy is often related to the lipophilic features exhibited both by long carbo-chains and the phosphine ligands. Three Ru(II) complexes containing hydroxy stearic acids (HSAs) were successfully synthesized in order to evaluate possible synergistic effects between the known antitumor activity of HSA bio-ligands and the metal center. HSAs were reacted with [Ru(H)2CO(PPh3)3] selectively affording O,O-carboxy bidentate complexes. The organometallic species were fully characterized spectroscopically using ESI-MS, IR, UV-Vis, and NMR techniques. The structure of the compound Ru-12-HSA was also determined using single crystal X-ray diffraction. The biological potency of ruthenium complexes (Ru-7-HSA, Ru-9-HSA, and Ru-12-HSA) was studied on human primary cell lines (HT29, HeLa, and IGROV1). To obtain detailed information about anticancer properties, tests for cytotoxicity, cell proliferation, and DNA damage were performed. The results demonstrate that the new ruthenium complexes, Ru-7-HSA and Ru-9-HSA, possess biological activity. Furthermore, we observed that the Ru-9-HSA complex shows increased antitumor activity on colon cancer cells, HT29. Full article
(This article belongs to the Special Issue Synthesis and Applications in Catalysis or as Anticancer and Antimicrobial Agents of Unique Organometallic Compounds)
►▼ Show Figures

Figure 1

50 pages, 7553 KiB  
Article
Half-Sandwich Type Platinum-Group Metal Complexes of C-Glucosaminyl Azines: Synthesis and Antineoplastic and Antimicrobial Activities
by István Kacsir, Adrienn Sipos, Evelin Major, Nikolett Bajusz, Attila Bényei, Péter Buglyó, László Somsák, Gábor Kardos, Péter Bai and Éva Bokor
Molecules 2023, 28(7), 3058; https://doi.org/10.3390/molecules28073058 - 29 Mar 2023
Cited by 1 | Viewed by 1795
Abstract
While platinum-based compounds such as cisplatin form the backbone of chemotherapy, the use of these compounds is limited by resistance and toxicity, driving the development of novel complexes with cytostatic properties. In this study, we synthesized a set of half-sandwich complexes of platinum-group [...] Read more.
While platinum-based compounds such as cisplatin form the backbone of chemotherapy, the use of these compounds is limited by resistance and toxicity, driving the development of novel complexes with cytostatic properties. In this study, we synthesized a set of half-sandwich complexes of platinum-group metal ions (Ru(II), Os(II), Ir(III) and Rh(III)) with an N,N-bidentate ligand comprising a C-glucosaminyl group and a heterocycle, such as pyridine, pyridazine, pyrimidine, pyrazine or quinoline. The sugar-containing ligands themselves are unknown compounds and were obtained by nucleophilic additions of lithiated heterocycles to O-perbenzylated 2-nitro-glucal. Reduction of the adducts and, where necessary, subsequent protecting group manipulations furnished the above C-glucosaminyl heterocycles in their O-perbenzylated, O-perbenzoylated and O-unprotected forms. The derived complexes were tested on A2780 ovarian cancer cells. Pyridine, pyrazine and pyridazine-containing complexes proved to be cytostatic and cytotoxic on A2780 cells, while pyrimidine and quinoline derivatives were inactive. The best complexes contained pyridine as the heterocycle. The metal ion with polyhapto arene/arenyl moiety also impacted on the biological activity of the complexes. Ruthenium complexes with p-cymene and iridium complexes with Cp* had the best performance in ovarian cancer cells, followed by osmium complexes with p-cymene and rhodium complexes with Cp*. Finally, the chemical nature of the protective groups on the hydroxyl groups of the carbohydrate moiety were also key determinants of bioactivity; in particular, O-benzyl groups were superior to O-benzoyl groups. The IC50 values of the complexes were in the low micromolar range, and, importantly, the complexes were less active against primary, untransformed human dermal fibroblasts; however, the anticipated therapeutic window is narrow. The bioactive complexes exerted cytostasis on a set of carcinomas such as cell models of glioblastoma, as well as breast and pancreatic cancers. Furthermore, the same complexes exhibited bacteriostatic properties against multiresistant Gram-positive Staphylococcus aureus and Enterococcus clinical isolates in the low micromolar range. Full article
(This article belongs to the Special Issue Synthesis and Applications in Catalysis or as Anticancer and Antimicrobial Agents of Unique Organometallic Compounds)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop